Ardelyx, Inc. (ARDX) Stock Price

ARDXStock

$3.78−38.79%52W

Market Cap$975.95M

P/E—

PEG Ratio—

Div yield—

Beta0.64

ARDX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-55.59%

Price vs S&P 500 (4W)-29.50%

VGM Score45.28

Book Value / Share (Quarterly)$0.60

P/TBV (Annual)10.34x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)98.40%

Cash Flow / Share (Quarterly)$-0.07

Price vs S&P 500 (YTD)-47.81%

Gross Margin (TTM)94.37%

Net Profit Margin (TTM)-12.35%

EPS (TTM)$-0.23

10-Day Avg Trading Volume4.49M

EPS Excl Extra (TTM)$-0.23

Revenue Growth (5Y)121.91%

EPS (Annual)$-0.26

ROI (Annual)-16.66%

Gross Margin (Annual)90.29%

Net Profit Margin (5Y Avg)-354.96%

Cash / Share (Quarterly)$1.13

Revenue Growth QoQ (YoY)23.77%

ROA (Last FY)-12.28%

Revenue Growth TTM (YoY)16.77%

EBITD / Share (TTM)$-0.13

ROE (5Y Avg)-71.79%

Operating Margin (TTM)-7.86%

Cash Flow / Share (Annual)$-0.18

P/B Ratio6.54x

P/B Ratio (Quarterly)8.45x

Net Income / Employee (Annual)$-126,000

EV / Revenue (TTM)2.50x

Net Interest Coverage (TTM)-2.02x

ROA (TTM)-10.77%

EV / EBITDA (TTM)520.26x

EPS Incl Extra (Annual)$-0.26

Current Ratio (Annual)4.31x

Quick Ratio (Quarterly)2.89x

3-Month Avg Trading Volume4.11M

52-Week Price Return-38.79%

Revenue / Employee (TTM)$922,100

Tangible BV / Share (Quarterly)$0.82

P/S Ratio (Annual)2.39x

Asset Turnover (Annual)0.81x

52-Week High$8.40

Operating Margin (5Y Avg)-343.95%

EPS Excl Extra (Annual)$-0.26

CapEx CAGR (5Y)36.06%

Tangible BV CAGR (5Y)-6.73%

26-Week Price Return-44.35%

Quick Ratio (Annual)3.80x

13-Week Price Return-41.10%

Total Debt / Equity (Annual)1.21x

Current Ratio (Quarterly)3.34x

Enterprise Value$1.13B

Revenue / Share Growth (5Y)82.05%

Asset Turnover (TTM)0.87x

Book Value / Share Growth (5Y)-12.70%

Revenue / Employee (Annual)$833,000

Inventory Turnover (Annual)2.03x

Pretax Margin (Annual)-14.89%

Cash / Share (Annual)$1.08

3-Month Return Std Dev52.04%

Gross Margin (5Y Avg)88.61%

Net Income / Employee (TTM)$-113,900

ROE (Last FY)-36.90%

Net Interest Coverage (Annual)-1.51x

EPS Basic Excl Extra (Annual)$-0.26

P/FCF (TTM)46.84x

Receivables Turnover (TTM)5.54x

EV / Free Cash Flow (TTM)976.57x

Total Debt / Equity (Quarterly)1.69x

EPS Incl Extra (TTM)$-0.23

Receivables Turnover (Annual)6.29x

ROI (TTM)-15.06%

P/S Ratio (TTM)2.16x

Pretax Margin (5Y Avg)-354.79%

Revenue / Share (Annual)$1.69

Tangible BV / Share (Annual)$0.50

Forward P/E21.58x

Price vs S&P 500 (52W)-57.10%

Year-to-Date Return-35.85%

5-Day Price Return-4.59%

EPS Normalized (Annual)$-0.26

ROA (5Y Avg)-36.87%

Net Profit Margin (Annual)-15.12%

Month-to-Date Return-24.44%

Cash Flow / Share (TTM)$0.01

EBITD / Share (Annual)$-0.16

Operating Margin (Annual)-10.06%

LT Debt / Equity (Annual)1.21x

ROI (5Y Avg)-50.13%

LT Debt / Equity (Quarterly)1.69x

EPS Basic Excl Extra (TTM)$-0.23

P/TBV (Quarterly)5.32x

P/B Ratio (Annual)8.48x

Inventory Turnover (TTM)1.06x

Pretax Margin (TTM)-12.30%

Book Value / Share (Annual)$0.68

Price vs S&P 500 (13W)-43.90%

Beta0.64x

P/FCF (Annual)84.43x

Revenue / Share (TTM)$1.82

ROE (TTM)-36.00%

52-Week Low$3.73

vGradeD

gGradeB

mGradeD

vgmGradeC

ARDX Earnings Surprise History

Q2 25-0.08est. -0.14

Q3 250.00est. -0.07

Q4 250.00est. 0.01

Q1 26-0.15est. -0.14

Q2 26-0.07est. -0.05

ARDX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.47

4.50

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ARDXArdelyx, Inc.	D	B	D	$3.78
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Ardelyx, Inc.

Ardelyx Inc is a biopharmaceutical company developing first-in-class medicines for unmet medical needs using a proprietary platform designed to minimize side effects and drug-drug interactions. The company's marketed products include IBSRELA (tenapanor) for irritable bowel syndrome with constipation in adults, and XPHOZAH (tenapanor) for reducing serum phosphorus in dialysis patients with chronic kidney disease who have inadequate response to or intolerance of phosphate binders.